Pfizer agreed on Thursday to acquire Hospira, a provider of injectable drugs and biosimilars, for about $17bn in it's first big deal since it failed to buy AstraZeneca last year. The New York-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results